XPER Research Acquires Lorentis to Strengthen Its Position as a Dedicated CRO for Medical Devices and In Vitro Diagnostics
Oudenaarde (BE), 6 May 2025 – XPER Research, a full-service Contract Research Organization (CRO) specialized in clinical research for medical devices and in vitro diagnostics (IVD), is proud to announce the acquisition of Lorentis, a Belgium-based consultancy company dedicated to medical and regulatory writing for medical devices and IVDs. This strategic move reinforces XPER’s commitment to become the go-to boutique CRO for the MedTech and IVD sectors across the globe.
Lorentis has built a strong reputation for its scientific expertise and agility in the preparation of clinical, regulatory, and performance evaluation documentation under MDR and IVDR. With this acquisition, XPER Research expands its offering by integrating Lorentis’ specialized medical and regulatory writing services without compromising the personalized service and quality that clients have come to appreciate.
“This acquisition is a natural fit for both companies,” says Jan Eelen, CEO of XPER Research. “By joining forces with Lorentis, we are bringing exceptional medical and regulatory writing capabilities in-house, which allows us to provide more integrated and streamlined services to our clients.”
Together, XPER and Lorentis are well positioned for accelerated growth and committed to scientific excellence, regulatory compliance, and expert support tailored to the unique needs of MedTech innovators.
Contact
Jan Eelen
CEO
jan.eelen@xperresearch.com
About XPER Research
XPER Research is a boutique Contract Research Organization (CRO) specialized in customized clinical research solutions for the medical device industry. By combining deep industry expertise with a commitment to excellence and client success, XPER Research partners with MedTech companies to deliver high-quality results on time and within budget.
XPER Research
Together, let’s IMPACT Clinical Research.
